Ex Vivo Permeation of Carprofen Vehiculated by PLGA Nanoparticles through Porcine Mucous Membranes and Ophthalmic Tissues

dc.contributor.authorGómez, Lidia
dc.contributor.authorParra Coca, Alexander
dc.contributor.authorCalpena Campmany, Ana Cristina
dc.contributor.authorGimeno Sandig, Álvaro
dc.contributor.authorGómez de Aranda Pulgarín, Inmaculada
dc.contributor.authorBoix Montañés, Antonio de Pádua
dc.date.accessioned2020-05-21T07:22:00Z
dc.date.available2020-05-21T07:22:00Z
dc.date.issued2020-02-18
dc.date.updated2020-05-21T07:22:01Z
dc.description.abstract(1) Background: Carprofen (CP), 2-(6-chlorocarbazole) propionic acid, is used as an anti-inflammatory, analgesic and anti-pyretic agent and it belongs to the family of non-steroidal anti-inflammatory drugs (NSAIDs). CP has some adverse reactions in systemic administration; for this reason, topical administration with CP nanoparticles (CP-NPs) can be an optimal alternative. The main objective of this work is the investigation of ex vivo permeation of CP through different types of porcine mucous membranes (buccal, sublingual and vaginal) and ophthalmic tissues (cornea, sclera and conjunctiva) to compare the influence of CP-NPs formulation over a CP solution (CP-Solution). (2) Methods: The ex vivo permeation profiles were evaluated using Franz diffusion cells. Furthermore, in vivo studies were performed to verify that the formulations did not affect the cell structure and to establish the amount retained (Qr) in the tissues. (3) Results: Permeation of CP-NPs is more effective in terms of drug retention in almost all tissues (with the exception of sclera and sublingual). In vivo studies show that neither of the two formulations affects tissue structure, so both formulations are safe. (4) Conclusions: It was concluded that CP-NPs may be a useful tool for the topical treatment of local inflammation in veterinary and human medicine.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec699241
dc.identifier.issn2079-4991
dc.identifier.pmid30279564
dc.identifier.urihttps://hdl.handle.net/2445/161798
dc.language.isoeng
dc.publisherMDPI
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.3390/nano10020355
dc.relation.ispartofNanomaterials, 2020, vol. 10, num. 2, p. 355
dc.relation.urihttps://doi.org/10.3390/nano10020355
dc.rightscc-by (c) Gomez, Lidia et al., 2020
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es
dc.sourceArticles publicats en revistes (Farmàcia, Tecnologia Farmacèutica i Fisicoquímica)
dc.subject.classificationNanopartícules
dc.subject.classificationSolucions (Farmàcia)
dc.subject.classificationSistemes d'alliberament de medicaments
dc.subject.classificationAgents antiinflamatoris
dc.subject.classificationMalalties dels animals
dc.subject.classificationPorc
dc.subject.classificationAssaigs clínics
dc.subject.otherNanoparticles
dc.subject.otherSolutions (Pharmacy)
dc.subject.otherDrug delivery systems
dc.subject.otherAntiinflammatory agents
dc.subject.otherAnimal diseases
dc.subject.otherSwine
dc.subject.otherClinical trials
dc.titleEx Vivo Permeation of Carprofen Vehiculated by PLGA Nanoparticles through Porcine Mucous Membranes and Ophthalmic Tissues
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
699241.pdf
Mida:
5.85 MB
Format:
Adobe Portable Document Format